Morgan Stanley
DNA icon

Morgan Stanley’s Ginkgo Bioworks DNA Stock Holding History

Morgan Stanley’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Sell
144,314
-315,686
-69% -$2.64M ﹤0.01% 5041
2026
Q1 		$2.82M Sell
460,000
-306,487
-40% -$2.55M ﹤0.01% 4512
2025
Q4 		$6.37M Buy
766,487
+445,765
+139% +$4.8M ﹤0.01% 3997
2025
Q3 		$4.68M Sell
320,722
-188,811
-37% -$2.26M ﹤0.01% 4210
2025
Q2 		$5.73M Sell
509,533
-126,186
-20% -$978K ﹤0.01% 3949
2025
Q1 		$3.62M Buy
635,719
+70,447
+12% +$718K ﹤0.01% 4196
2024
Q4 		$5.55M Buy
565,272
+293,474
+108% +$2.52M ﹤0.01% 3906
2024
Q3 		$2.22M Buy
271,798
+121,823
+81% +$1.22M ﹤0.01% 4574
2024
Q2 		$2.01M Sell
149,975
-1,076,807
-88% -$32.1M ﹤0.01% 4565
2024
Q1 		$56.9M Buy
1,226,782
+2,712
+0.2% +$140K ﹤0.01% 1633
2023
Q4 		$82.7M Sell
1,224,070
-20,116
-2% -$1.23M 0.01% 1297
2023
Q3 		$90.1M Buy
1,244,186
+42,651
+4% +$3.41M 0.01% 1126
2023
Q2 		$89.4M Sell
1,201,535
-274,475
-19% -$16.2M 0.01% 1161
2023
Q1 		$78.5M Buy
1,476,010
+198,904
+16% +$12.6M 0.01% 1208
2022
Q4 		$86.3M Sell
1,277,106
-78,994
-6% -$7.27M 0.01% 1120
2022
Q3 		$169M Buy
1,356,100
+375,774
+38% +$44.8M 0.02% 639
2022
Q2 		$93.3M Buy
980,326
+355,839
+57% +$43.4M 0.01% 963
2022
Q1 		$101M Buy
624,487
+261,113
+72% +$50.8M 0.01% 863
2021
Q4 		$121M Buy
363,374
+81,513
+29% +$38.7M 0.01% 781
2021
Q3 		$131M Buy
+281,861
New +$137M 0.02% 699

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Morgan Stanley's DNA Position: Q2 2026 in Review

Morgan Stanley reduced its Ginkgo Bioworks (DNA) stake by 69% in Q2 2026, selling an estimated $2.64M and leaving 144,314 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #5041.

Morgan Stanley first reported a position in DNA in Q3 2021 and has held it in 20 quarters since. The position peaked at $169M in Q3 2022. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Morgan Stanley held 144,314 shares of Ginkgo Bioworks worth $1.43M as of Q2 2026.
  • Morgan Stanley sold 315,686 Ginkgo Bioworks shares in Q2 2026, an estimated $2.64M.
  • Ginkgo Bioworks made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5041 holding.
  • Morgan Stanley first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Ginkgo Bioworks position peaked at $169M in Q3 2022.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.